ClinicalTrials.gg
RecruitingNCT02469662Updated Jul 9, 2026

Clinical Outcomes Study of the Nexel Total Elbow

An interventional study of Nexel Total Elbow in Elbow Joint Destruction, Post-traumatic Lesions and Ankylosed Joints, sponsored by Zimmer Biomet. Recruiting at 11 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Zimmer Biomet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2015; still recruiting 11 years 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objectives of the study are to confirm safety and performance of the Zimmer Nexel Total Elbow when used in primary or revision total elbow replacement.

Read the detailed description

The objectives of the study are to confirm safety and performance of the Zimmer® Nexel™ Total Elbow when used in primary or revision total elbow replacement by analysis of standard scoring systems, radiographs, and adverse event records.

The safety of the device will be monitored using the frequency and incidence of reporting adverse events.

The performance of the device will be evaluated by assessing the pain and functional performance, survival of the device, patient health status, and radiographic success of the implant.

02

Conditions studied

  • Elbow Joint Destruction
  • Post-traumatic Lesions
  • Ankylosed Joints
  • Advanced Rheumatoid Arthritis
  • Joint Instability or Loss of Motion
  • Acute Comminuted Articular Fracture of Elbow Joint Surfaces
  • Bone Loss Contributing to Elbow Instability
  • Bilateral Ankylosis From Causes Other Than Active Sepsis
  • Post-traumatic Arthritis
  • Degenerative Arthritis

Keywords

  • Total Elbow Arthroplasty
  • TEA
  • Elbow Arthroplasty
  • Elbow Replacement
  • Advanced Rheumatoid Arthritis
  • Post-Traumatic Arthritis
  • Degenerative Arthritis
  • Elbow Joint Destruction
  • Post-Traumatic Lesions or Bone Loss
  • Ankylosed Joints
  • Acute Comminuted Articular Fracture
  • Significantly compromises daily living activities
  • Joint or soft tissue damage
  • Precludes less radical procedures
  • 13-C3 fractures of the distal humerus
03

In context

Ankylosis

83 studies on the registry are indexed under Ankylosis; 18 are open to participants now.

This study's planned enrollment of 134 is above the median of 99 across 34 interventional studies indexed under Ankylosis.

Browse Ankylosis studies →

Lead sponsor

Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is 18 years of age or older.
  • Patient must have signed Institutional Review Board (IRB)/Ethics Committee (EC)-approved .
  • Patient is a candidate for primary or revision total elbow arthroplasty, based on symptoms including at least one of the following:

    • Elbow joint destruction which significantly compromises daily living activities
    • Post-traumatic lesions or bone loss contributing to elbow instability
    • Ankylosed joints, especially cases of bilateral ankylosis from causes other than active sepsis
    • Advanced rheumatoid arthritis, post-traumatic, or degenerative arthritis with incapacitating pain
    • Instability or loss of motion when the degree of joint or soft tissue damage precludes reliable osteosynthesis
    • Acute comminuted articular fracture of elbow joint surfaces that precludes less radical procedures, including 13-C3 fractures of the distal humerus
  • Patient is willing and able to complete scheduled follow-up evaluations as defined by the protocol.

Additional Retrospective Arm Inclusion Criteria

  • Patient must have undergone a total elbow replacement with the Nexel system between July 2013 and the date of the site initiation visit.
  • Patient information available for each retrospective patient must, at minimum, include preoperative demographic information, preoperative physical exam information, the index surgery operative report, and details of the devices implanted.

Exclusion criteria

Exclusion Criteria:

  • Patient has a currently active or history of repeated local infection at the surgical site.
  • Patient has a current major infection distant from the operative site.
  • Patient has a history of prior sepsis.
  • Patient suffers from paralysis or dysfunctional neuropathy at the elbow joint.
  • Patient has significant ipsilateral hand dysfunction.
  • Patient has excessive scarring near the surgical site, which could prevent adequate soft tissue coverage.
  • Patient participates in daily activities that may cause significant stress to an implanted device such as heavy labor, torsional stress, and/or competitive sports.
  • Patient is a prisoner.
  • Patient is mentally incompetent or unable to understand what participation in the study entails.
  • Patient is a known alcohol or drug abuser.
  • Patient is anticipated to be non-compliant.
  • Patient is known to be pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (estimated)

Study arms

  • Experimental
    Retrospective

    Patients who have had primary or revision total elbow arthroplasty using the Nexel Total Elbow, and who have surgical details available

    Device: Nexel Total Elbow

  • Experimental
    Prospective

    Patients who are having primary or revision total elbow arthroplasty who will receive the Nexel Total Elbow

    Device: Nexel Total Elbow

Interventions

  • DeviceNexel Total Elbow

    Nexel Total Elbow used in primary or revision total elbow arthroplasty

    Also known as: Nexel Elbow, Nexel

06

What researchers measure

Primary outcomes

  1. Survivorship

    Based on removal or intended removal of the device and determined using the Kaplan-Meier method

    Time frame: 10 years

07

Study locations

7 of 11 sites recruiting
  • Panorama Orthopedics and Spine Center
    Golden, Colorado 80401, United States
    Recruiting
  • OrthoCarolina Research Institute
    Charlotte, North Carolina 28207, United States
    Recruiting
  • Rothman Institute
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Campbell Clinic
    Germantown, Tennessee 38138, United States
    Recruiting
  • Sydney Shoulder & Elbow, NSW
    Sydney, New South Wales 2067, Australia
    Terminated

    Not enrolling at this site.

  • Coxa Hospital
    Tampere, Finland
    Recruiting
    • Pirjo Honkanen, MD · Principal investigator
  • Hôpital Purpan (Centre Hospitalier Universitaire Toulouse)
    Toulouse, France
    Terminated

    Not enrolling at this site.

  • Arcus Sportklinik
    Pforzheim, Germany
    Terminated

    Not enrolling at this site.

  • AO Mauriziano
    Torino, 10128, Italy
    Recruiting
  • Amphia Ziekenhuis Breda
    Breda, Netherlands
    Active, not recruiting

    Not enrolling at this site.

  • Wrightington
    Wigan, United Kingdom
    Recruiting
    • Adam Watts, MBBS · Principal investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02469662
Lead sponsor
Zimmer Biomet
Responsible party
Sponsor
First posted
Jun 11, 2015
Start date
Jun 2015
Primary completion
Dec 2035 (estimated)
Completion
Dec 2036 (estimated)
Last update
Jul 9, 2026

Study contacts

Richard Marek
Contact
richard.marek@zimmerbiomet.com
574-453-7567
Ryan Boylan
Contact
ryan.boylan@zimmerbiomet.com
574-527-7934
Hillary Overholser, MS
study director · Zimmer Biomet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion